<SEC-DOCUMENT>0001193125-20-139927.txt : 20200512
<SEC-HEADER>0001193125-20-139927.hdr.sgml : 20200512
<ACCEPTANCE-DATETIME>20200512105806
ACCESSION NUMBER:		0001193125-20-139927
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200508
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200512
DATE AS OF CHANGE:		20200512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				364787690
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38445
		FILM NUMBER:		20867448

	BUSINESS ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-944-6104

	MAIL ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC
		DATE OF NAME CHANGE:	20180517

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20140613
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d927780d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;8, 2020 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g927780dsp001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>HELIUS MEDICAL TECHNOLOGIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>DELAWARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38445</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">36-4787690</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>642 Newtown Yardley Road, Suite 100</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Newtown, PA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>18940</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s Telephone Number, Including Area Code: (215)
<FONT STYLE="white-space:nowrap">944-6100</FONT> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>HSDT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;&nbsp;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&nbsp;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;8, 2020, Philippe Deschamps, President and Chief
Executive Officer of Helius Medical Technologies, Inc. (the &#147;<I>Company</I>&#148;), elected to temporarily reduce his base salary by thirty percent (30%) until his revocation due to current industry-wide conditions, including the uncertainty
created by the effects of the novel coronavirus <FONT STYLE="white-space:nowrap">(COVID-19).</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2020, the Company issued a press release announcing that the U.S. Food and Drug Administration granted Breakthrough Designation
for its PoNS<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis, to be used as an adjunct to a supervised therapeutic exercise program. A copy of the
press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward- Looking Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> contains certain forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, and Canadian securities laws, including those relating to the Company&#146;s product
development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive
in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management&#146;s current beliefs and assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statements may be identified by the use of forward-looking expressions, including, but not limited to, &#147;expect,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;would&#148; and similar expressions and the negatives
of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company&#146;s filings with the SEC. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future events or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d927780dex991.htm">Press Release, dated May 12, 2020.</A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>HELIUS MEDICAL TECHNOLOGIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May&nbsp;12, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joyce LaViscount</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joyce LaViscount</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d927780dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g927780g0512053720147.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEWTOWN, Pa. | May</B><B></B><B>&nbsp;12, 2020</B> - <B></B>Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (&#147;Helius&#148; or the
&#147;Company&#148;), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation for its PoNS<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> device as a potential treatment for
gait deficit due to symptoms of Multiple Sclerosis (&#147;MS&#148;), to be used as an adjunct to a supervised therapeutic exercise program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are
extremely pleased to receive this designation for our PoNS device,&#148; said Philippe Deschamps, the Company&#146;s CEO. &#147;We look forward to working with FDA to process our application, with the ultimate goal of bringing our innovative
technology to the aid of patients suffering with gait deficit due to <FONT STYLE="white-space:nowrap">MS-related</FONT> symptoms, by providing them with a <FONT STYLE="white-space:nowrap">non-drug,</FONT>
<FONT STYLE="white-space:nowrap">non-implantable</FONT> treatment that has the potential to significantly improve their ability to walk.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Breakthrough Devices Program is a voluntary program for certain medical devices and <FONT STYLE="white-space:nowrap">device-led&nbsp;combination</FONT> products&nbsp;that provide for more effective treatment or diagnosis of life-threatening or
irreversibly debilitating diseases or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The goal of the Breakthrough Devices Program is to provide patients and health care providers with
timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with FDA&#146;s
mission to protect and promote public health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Breakthrough Devices Program replaces the Expedited Access Pathway and Priority Review for medical
devices. The FDA considers devices granted designation under the Expedited Access Pathway to be part of the Breakthrough Devices Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Breakthrough Devices Program offers manufacturers an opportunity to interact with the FDA&#146;s experts through several different program options to efficiently address topics as they arise during the premarket review phase, which can help
manufacturers receive feedback from the FDA and identify areas of agreement in a timely way. Manufacturers can also expect prioritized review of their submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important to note that Breakthrough Device Designation does not change the requirements for approval of an application for a marketing authorization
under section 510(k) of the Food, Drug, and Cosmetic Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Helius Medical Technologies, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company&#146;s purpose is to develop, license and acquire unique and <FONT
STYLE="white-space:nowrap">non-invasive</FONT> platform technologies that amplify the brain&#146;s ability to heal itself. The Company&#146;s first product in development is the Portable Neuromodulation Stimulator (PoNS<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP>). For more information, visit <U>www.heliusmedical.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the PoNS Device and PoNS Treatment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Portable Neuromodulation Stimulator (PoNS) is an authorized class II, <FONT STYLE="white-space:nowrap">non-implantable</FONT> medical device authorized for
sale in Canada. PoNS is intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy and indicated as a short term treatment (14 weeks) chronic balance
deficit due to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mild-to-moderate</FONT></FONT> traumatic brain injury and is to be used in conjunction with physical therapy. The PoNS is an investigational medical device in the
United States, the European Union, and Australia, and is currently under review for clearance by the AUS Therapeutic Goods Administration. PoNS Treatment is currently not commercially available in the United States, the European Union or Australia.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Disclaimer Statement:</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements
in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All
statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as &#147;believe,&#148;
&#147;continue,&#148; &#147;look forward,&#148; &#147;will&#148; and similar expressions. Such forward-looking statements include, among others, statements regarding the Company&#146;s future clinical and regulatory development plans for the PoNS,
the success of the Company&#146;s planned study, business and commercialization initiatives and objectives, the potential receipt of regulatory clearance of the PoNS device in the United States, the European Union and Australia and the
Company&#146;s revenue guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that such statements will prove to be accurate and actual results and future events could
differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company&#146;s expectations include the uncertainties associated with clinical trial enrollments
and the results of clinical trials, uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including the Company&#146;s capital requirements to achieve its business objectives and other
risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company&#146;s business described in the &#147;Risk Factors&#148; sections of the Company&#146;s
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, and Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020 filed on May&nbsp;11, 2020 and its other
filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made
as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners on behalf of Helius Medical Technologies, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Piccinino, CFA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">443-213-0500</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investorrelations@heliusmedical.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g927780dsp001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g927780dsp001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M*U>=:5Y,^GH8>&'CRP1Z!X&_Y%M/^NK5[N7?P/F?/YG_ +Q\D=)7H'FA0 4
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M[:6XGDC6/SI-N],9P5P  <G/3K0!:LM*%C<S2Q7EP8YI&E:%MFW<W7^'/ZT
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M4,%VYX4'WQG&: -.@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
'H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g927780g0512053720147.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g927780g0512053720147.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 +D# 2(  A$! Q$!_\0
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M@?A]Q<W_ /N)_,UWF[BM\!.4Z"E)W>OYF&80C3Q$HQ5DK?D.HHHKL.(****
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M&]UY!<$YQNQGZT >A4444 %%%8?BW4+G2O#5U>6CA9H]FTD9ZL : -RBN(\
M^(=1UV2^%]*'$00IA<8SG/\ *L;6?'.MV7B.ZL8/*\F*?RUS%DXX[T >H44@
MI: "BBB@ HHHH **** ..\?_ /(,L_\ KL?_ $$UP%=_X_\ ^099_P#78_\
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MAYA\5/\ C_TW_KD_\Q6]X/T'2KOPII]Q<6$,DKQG<[+R?F-8/Q5_X_\ 3?\
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M6]"C[.-F<&-Q7UBIS)62*EWIME?,K75I#.4^Z9$!Q4UO!#:PI#!&L<2<*B#
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+HN,GUJS110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
